Ibandronate: A Comparison of Oral Daily Dosing Versus Intermittent Dosing in Postmenopausal Osteoporosis

Riis, Bente Juel; Ise, J.; Stein, Tricia; Bagger, Yu Z.; Christiansen, Claus

doi:10.1359/jbmr.2001.16.10.1871

Cited by 98 publications

(47 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence of upper GI adverse events was only slightly higher in the clodronate group (22% for clodronate versus 19% for placebo) [43], but diarrhea was significantly more common in the clodronate group, particularly during the treatment period (15% versus 7%; p < 0.05). In a pooled analysis of two recent trials of oral ibandronate in breast cancer patients with bone metastases, [45,46]. In addition, a higher percentage of patients in the daily ibandronate group experienced constipation than in the placebo group (6% versus 0%).…”

Section: Oral Bisphosphonatesmentioning

confidence: 99%

Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens

2004

View full text Add to dashboard Cite

Patients with advanced cancers-particularly breast and prostate cancers-are at high risk for bone metastasis, leading to accelerated bone resorption and clinically significant skeletal morbidity. Bisphosphonates are effective inhibitors of bone resorption and reduce the risk of skeletal complications in patients with bone metastases. The standard routes of administration for bisphosphonates used in clinical practice are either oral or i.v. infusion. Oral administration of bisphosphonates is complicated by poor bioavailability (generally <5%) and poor gastrointestinal tolerability. First-generation bisphosphonates, such as clodronate (Bonefos ® ; Anthra Pharmaceuticals; Princeton, NJ), must be administered at high oral doses (1,600-3,200 mg/day) to achieve therapeutic effects, which leads to poor tolerability and compliance with oral dosing regimens. Infusion of bisphosphonates is associated with dose-and infusionrate-dependent effects on renal function. In particular, high bisphosphonate doses (e.g., 1,500 mg clodronate) can cause severe renal toxicity unless infused slowly over many hours. In contrast, the newer, more potent bisphosphonates effectively inhibit bone resorption at micromolar concentrations, and the small doses required can be administered via relatively short i. The Oncologist 2004;9(suppl 4):28-37 www.TheOncologist.com

show abstract

Section: Oral Bisphosphonatesmentioning

confidence: 99%

Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens

2004

View full text Add to dashboard Cite

show abstract

“…Осо-бый интерес представляют исследования на животных, ко-торые показали, что терапевтическая эффективность ибан-дроната определяется кумулятивной дозой за определен-ный период, а не частотой назначения [15][16][17][18]. Затем был проведен ряд клинических исследований влияния различ-ных доз ибандроната на МПК, уровень биохимических маркеров, риск развития новых переломов и переноси-мость, продемонстрировавших высокую эффективность и безопасность препарата у человека [19,20]. Эквивалентная эффективность общей дозы независимо от режима введе-ния позволила назначать его прерывисто и людям.…”

Section: гу институт ревматологии рамн москваunclassified

Biophosphonates: adherence to therapy is a pledge of successful treatment for osteoporosis

Торопцова¹,

Benevolenskaya²

2008

Modern Rheumatology Journal

View full text Add to dashboard Cite

Остеопороз (ОП) занимает 4-е место среди хронических заболеваний, сопровождается высокими показателями ин-валидности и смертности во второй половине жизни, в ре-зультате чего общество несет значительные материальные потери. Важность проблемы ОП подтверждают данные ли-тературы, свидетельствующие о его высокой распространен-ности практически во всех странах. В России среди обследо-ванных в возрасте 50 лет и старше ОП выявлен у 30,5-33,1% женщин и 22,8-24,1% мужчин. Следовательно, каждая тре-тья женщина и каждый пятый мужчина этой возрастной группы имеют ОП. Если пересчитать эти данные на все на-селение России (145 167 тыс. человек -данные переписи 2002 г.), то число больных может превышать 10 млн [1]. Кроме того, постарение населения во всем мире обусловли-вает постоянный рост частоты ОП. Так, к 2010 г. в Европе людей старше 60 лет будет больше, чем молодых в возрасте до 20 лет, а в 2020 г. они будут составлять уже четверть всего населения. В России 16% населения старше 60 лет, а к 2015 г. прогнозируется увеличение этого показателя до 20%. Соци-альное значение ОП определяется его последствиями -пе-реломами при низком уровне травмы с характерной локали-зацией -позвонки и трубчатые кости. В возрасте 50 лет и старше остеопоротический перелом возникает у каждой третьей женщины и каждого восьмого мужчины.Для предотвращения прогрессирования ОП необхо-димо нормализовать процесс костного ремоделирова-ния, что должно привести к увеличению или стабилиза-ции минеральной плотности кости (МПК), улучшению качества кости и снижению частоты новых переломов. Клинически это проявляется уменьшением болевого синдрома, расширением двигательной активности, улуч-шением качества жизни.В настоящее время для лечения уже развившегося ОП и предупреждения новых переломов используют

show abstract

“…All clinical studies having assessed the antifracture efficacy of continuous daily administration of calcitonin, SERMs, or bisphosphonates in osteoporosis used a combination regimen where calcium and/or vitamin D were given on the same day [2][3][4][5]11,12] as the primary study medication. When other regimens than daily were privileged, as was the case for etidronate, given orally for 14 days every 15 weeks [13], or more recently, for the weekly oral administration of alendronate or risedronate [14], and for the intermittent injection of ibandronate (3-monthly) [15] or zoledronate (yearly) [16], calcium and/or vitamin D were also used as add-on therapy, given continuously or on days without intake of the bisphosphonate.…”

Section: Combination Use Of Two or More Inhibitors Of Bone Resorptionmentioning

confidence: 99%

Combination/sequential therapy in osteoporosis

Lecart¹,

Bruyère

Reginster³

2004

Curr Osteoporos Rep

View full text Add to dashboard Cite

Combination therapy includes the concomitant or sequential use of compounds sharing the same mode of action (eg, two or more inhibitors of bone resorption) or with distinct pathways of activity (eg, an inhibitor of resorption plus an anabolic agent). Combination use of antiresorptive agents may generate concerns, because of the risk of inducing oversuppression of bone turnover. However, if low doses of estrogen, used for the management of climacteric symptoms, are insufficient to normalize bone turnover, the addition of a bisphosphonate to hormone therapy may prove to be useful to achieve this objective. Patients pretreated with inhibitors of resorption, who have not achieved a full therapeutic response, are good candidates for treatment with anabolic agents. The increase in bone turnover that comes after the introduction of parathyroid hormone (PTH) in patients treated with an antiresorptive agent is similar to that observed in treatment-naïve patients and the pattern of bone mineral density (BMD) increase is also identical, with the exception of a 6 month delay in the spine and hip BMD changes observed in prior alendronate-treated subjects. Current data discourage the concomitant use of alendronate and PTH since the bisphosphonate appears to blunt (in men and women) the anabolic action of PTH. Whether this applies to other bisphosphonates or inhibitors of resorption, remains unknown. The use of an inhibitor of bone resorption after completion of PTH treatment seems an appropriate way to maintain the skeletal benefits gained during therapy. Long-term clinical studies, using fractures as an endpoint should be initiated to better understand the clinical and pharmaco-economic interest of combination therapies in the management of osteoporosis.

show abstract

Ibandronate: A Comparison of Oral Daily Dosing Versus Intermittent Dosing in Postmenopausal Osteoporosis

Cited by 98 publications

References 20 publications

Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens

Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens

Biophosphonates: adherence to therapy is a pledge of successful treatment for osteoporosis

Combination/sequential therapy in osteoporosis

Contact Info

Product

Resources

About